Literature DB >> 33448339

PharmVar GeneFocus: CYP2B6.

Zeruesenay Desta1, Ahmed El-Boraie2, Li Gong3, Andrew A Somogyi4, Volker M Lauschke5, Collet Dandara6, Kathrin Klein7,8, Neil A Miller9,10, Teri E Klein3, Rachel F Tyndale2, Michelle Whirl-Carrillo3, Andrea Gaedigk11,10.   

Abstract

The Pharmacogene Variation Consortium (PharmVar) catalogs star (*) allele nomenclature for the polymorphic human CYP2B6 gene. Genetic variation within the CYP2B6 gene locus impacts the metabolism or bioactivation of clinically important drugs. Of particular importance are efficacy and safety concerns regarding: efavirenz, which is used for the treatment of HIV type-1 infection; methadone, a mainstay in the treatment of opioid use disorder and as an analgesic; ketamine, used as an antidepressant and analgesic; and bupropion, which is prescribed to treat depression and for smoking cessation. This GeneFocus provides a comprehensive overview and summary of CYP2B6 and describes how haplotype information catalogued by PharmVar is utilized by the Pharmacogenomics Knowledgebase (PharmGKB) and the Clinical Pharmacogenetics Implementation Consortium (CPIC).
© 2021 The Authors. Clinical Pharmacology & Therapeutics © 2021 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33448339      PMCID： PMC8693800          DOI： 10.1002/cpt.2166

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.903


  99 in total

1.  PCR-based haplotype determination to distinguish CYP2B6*1/*7 and *5/*6.

Authors:  Yuki Futatsugawa; Takahiro Kubota; Akihiro Ishiguro; Hiroshi Suzuki; Hiroshi Ishikawa; Tatsuji Iga
Journal:  Clin Chem       Date:  2004-08       Impact factor: 8.327

2.  Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.

Authors:  S R Faucette; R L Hawke; E L Lecluyse; S S Shord; B Yan; R M Laethem; C M Lindley
Journal:  Drug Metab Dispos       Date:  2000-10       Impact factor: 3.922

Review 3.  Recommendations for Clinical CYP2C19 Genotyping Allele Selection: A Report of the Association for Molecular Pathology.

Authors:  Victoria M Pratt; Andria L Del Tredici; Houda Hachad; Yuan Ji; Lisa V Kalman; Stuart A Scott; Karen E Weck
Journal:  J Mol Diagn       Date:  2018-02-21       Impact factor: 5.568

4.  Q172H replacement overcomes effects on the metabolism of cyclophosphamide and efavirenz caused by CYP2B6 variant with Arg262.

Authors:  Noritaka Ariyoshi; Miyuki Ohara; Mayumi Kaneko; Sakino Afuso; Takuya Kumamoto; Hiroyoshi Nakamura; Itsuko Ishii; Tsutomu Ishikawa; Mitsukazu Kitada
Journal:  Drug Metab Dispos       Date:  2011-08-05       Impact factor: 3.922

5.  Functional characterization of 26 CYP2B6 allelic variants (CYP2B6.2-CYP2B6.28, except CYP2B6.22).

Authors:  Takashi Watanabe; Kanako Sakuyama; Takamitsu Sasaki; Yuya Ishii; Masaaki Ishikawa; Noriyasu Hirasawa; Masahiro Hiratsuka
Journal:  Pharmacogenet Genomics       Date:  2010-07       Impact factor: 2.089

6.  Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals.

Authors:  M Rotger; H Tegude; S Colombo; M Cavassini; H Furrer; L Décosterd; J Blievernicht; T Saussele; H F Günthard; M Schwab; M Eichelbaum; A Telenti; U M Zanger
Journal:  Clin Pharmacol Ther       Date:  2007-01-18       Impact factor: 6.875

7.  Aberrant splicing caused by single nucleotide polymorphism c.516G>T [Q172H], a marker of CYP2B6*6, is responsible for decreased expression and activity of CYP2B6 in liver.

Authors:  Marco H Hofmann; Julia K Blievernicht; Kathrin Klein; Tanja Saussele; Elke Schaeffeler; Matthias Schwab; Ulrich M Zanger
Journal:  J Pharmacol Exp Ther       Date:  2008-01-02       Impact factor: 4.030

8.  Allelic decomposition and exact genotyping of highly polymorphic and structurally variant genes.

Authors:  Ibrahim Numanagić; Salem Malikić; Michael Ford; Xiang Qin; Lorraine Toji; Milan Radovich; Todd C Skaar; Victoria M Pratt; Bonnie Berger; Steve Scherer; S Cenk Sahinalp
Journal:  Nat Commun       Date:  2018-02-26       Impact factor: 14.919

9.  PharmVar and the Landscape of Pharmacogenetic Resources.

Authors:  Andrea Gaedigk; Michelle Whirl-Carrillo; Victoria M Pratt; Neil A Miller; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-11-23       Impact factor: 6.875

10.  CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.

Authors:  Ingrid F Metzger; Nimita Dave; Yvonne Kreutz; Jessica B L Lu; Raymond E Galinsky; Zeruesenay Desta
Journal:  Clin Transl Sci       Date:  2019-08-12       Impact factor: 4.689
View more
  9 in total

1.  Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.

Authors:  Yaya Kassogue; Brehima Diakite; Mamoudou Maiga; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Fousseyni Diarra; Zoumana Diarra; Mahamadou Karamoko Sawadogo; Yaya Goita; Sidi Boula Sissoko; Adama Seydou Sissoko; Nouhoum Guirou; Hind Dehbi; Sellama Nadifi; Sekou Bah; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Guimogo Dolo
Journal:  Pharmacogenet Genomics       Date:  2022-06-22       Impact factor: 2.000

2.  Quantitative Prediction of Drug Interactions Caused by Cytochrome P450 2B6 Inhibition or Induction.

Authors:  Veronica Di Paolo; Francesco Maria Ferrari; Italo Poggesi; Luigi Quintieri
Journal:  Clin Pharmacokinet       Date:  2022-07-20       Impact factor: 5.577

3.  zzm321990 zzm321990 Influence of CYP2B6 Pharmacogenetics on Stereoselective Inhibition and Induction of Bupropion Metabolism by Efavirenz in Healthy Volunteers.zzm321990 zzm321990

Authors:  Brandon T Gufford; Ingrid F Metzger; Nadia O Bamfo; Eric A Benson; Andrea R Masters; Jessica Bo Li Lu; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2022-07-07       Impact factor: 4.402

Review 4.  PharmVar GeneFocus: CYP3A5.

Authors:  Cristina Rodriguez-Antona; Jessica L Savieo; Volker M Lauschke; Katrin Sangkuhl; Britt I Drögemöller; Danxin Wang; Ron H N van Schaik; Andrei A Gilep; Arul P Peter; Erin C Boone; Bronwyn E Ramey; Teri E Klein; Michelle Whirl-Carrillo; Victoria M Pratt; Andrea Gaedigk
Journal:  Clin Pharmacol Ther       Date:  2022-02-24       Impact factor: 6.903

5.  Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation.

Authors:  Andrea Gaedigk; Scott T Casey; Michelle Whirl-Carrillo; Neil A Miller; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2021-06-29       Impact factor: 6.903

6.  Large variability in plasma efavirenz concentration in Papua New Guinea HIV/AIDS patients associated with high frequency of CYP2B6 516T allele.

Authors:  Natália Bordin Andriguetti; Helena Katherina Van Schalkwyk; Daniel Thomas Barratt; Joseph Tucci; Paul Pumuye; Andrew Alexander Somogyi
Journal:  Clin Transl Sci       Date:  2021-08-20       Impact factor: 4.689

7.  GABRA1 and GABRB2 Polymorphisms are Associated with Propofol Susceptibility.

Authors:  Youjie Zeng; Si Cao; Minghua Chen; Chao Fang; Wen Ouyang
Journal:  Pharmgenomics Pers Med       Date:  2022-02-09

8.  CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function.

Authors:  Katalin Mangó; Ádám Ferenc Kiss; Ferenc Fekete; Réka Erdős; Katalin Monostory
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

Review 9.  CYP2B6 Functional Variability in Drug Metabolism and Exposure Across Populations-Implication for Drug Safety, Dosing, and Individualized Therapy.

Authors:  Immaculate M Langmia; Katja S Just; Sabrina Yamoune; Jürgen Brockmöller; Collen Masimirembwa; Julia C Stingl
Journal:  Front Genet       Date:  2021-07-12       Impact factor: 4.599
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.